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Tinnitus
David Baguley, Don McFerran, Deborah Hall
Tinnitus is a common medical symptom that can be debilitating. Risk factors include hearing loss, ototoxic 
medication, head injury, and depression. At presentation, the possibilities of otological disease, anxiety, and depression 
should be considered. No eﬀ ective drug treatments are available, although much research is underway into 
mechanisms and possible treatments. Surgical intervention for any otological pathology associated with tinnitus 
might be eﬀ ective for that condition, but the tinnitus can persist. Available treatments include hearing aids when 
hearing loss is identiﬁ ed (even mild or unilateral), wide-band sound therapy, and counselling. Cognitive behavioural 
therapy (CBT) is indicated for some patients, but availability of tinnitus-speciﬁ c CBT in the UK is poor. The evidence 
base is strongest for a combination of sound therapy and CBT-based counselling, although clinical trials are 
constrained by the heterogeneity of patients with tinnitus.
Introduction
Although much progress has been made, tinnitus 
remains a scientiﬁ c and clinical enigma. The condition is 
very common, and, although many patients are not 
unduly troubled, others ﬁ nd the disorder life-changing. 
In this Seminar we outline current knowledge of tinnitus, 
and critically assess established and emerging treatment 
approaches.
Derived from the Latin verb tinnire (to ring), the term 
tinnitus describes the conscious perception of an auditory 
sensation in the absence of a corresponding external 
stimulus. Tinnitus can be subjective, when the experience 
is of the individual alone, or, less commonly, objective, 
when an observer can hear the tinnitus. The sensation is 
generally of an elementary nature—descriptions of 
hissing, sizzling, and ringing are common—although, in 
some cases, more complex sounds such as voices or music 
are perceived. When voices or music, or both, are heard as 
a form of tinnitus, the perceptions are indistinct and 
convey no meaning, in contrast with the auditory hallu-
cinations that can occur with psychotic illness. Tinnitus 
can sometimes be a rhythmical or pulsatile sound. 
Pulsatile tinnitus1 can be synchronous with the heartbeat, 
in which case a vascular origin is likely, or asynchronous, 
in which case myoclonus of middle-ear or palatal muscles 
is probable.2 Tinnitus can be constant or intermittent, and 
many patients experience more than one sound. It can be 
localised to one or both ears, or centrally within the head, 
although some patients describe an external point of 
origin. The onset of tinnitus can be abrupt, but it is insid-
ious in most cases. The perceived intensity can vary; for 
some people, exacerbation alongside stress arousal is clear. 
The heterogeneity of tinnitus experience is substantial and 
has hampered both basic science and treatment research.
Epidemiology
Prevalence studies of tinnitus have mostly been done in 
western Europe or the USA, and have methodological 
drawbacks, especially with production of an unambiguous 
deﬁ nition of tinnitus and phrasing of appropriate 
epidemiological questions. Consequently, the scatter of 
prevalence estimates is wide, although most study results 
have shown rates of between 10% and 15% of the adult 
population. The largest and most scientiﬁ cally reliable 
study was undertaken as part of the National Study of 
Hearing in England (n=48 313).3 The results of the study 
showed a prevalence of 10∙1% among adults, with the 
tinnitus described as moderately annoying by 2∙8% of 
respondents, severely annoying by 1∙6%, and at a level 
that severely aﬀ ected ability to lead a normal life by 0∙5%. 
Results from studies in Egypt,4 Japan,5 and Nigeria,6 
indicate tinnitus prevalence is broadly similar in these 
countries to in Europe and the USA.
The prevalence of troublesome tinnitus increases with 
age to 70 years; results of some studies show that it 
continues to increase thereafter, although others have 
shown it to diminish.3 Prevalence in men and women is 
similar.3 Prevalence in children is diﬃ  cult to estimate, but 
results of available studies suggest that tinnitus experience 
is common, with ﬁ gures similar to those in adults.7 
Children, however, seem less likely to be distressed by the 
perception.7
The table shows known risk factors for developing 
tinnitus and associated conditions. The main risk factor 
is hearing loss,9 but this association is not simple or 
straightforward;3 some people with troublesome tinnitus 
have audiometrically normal hearing and, conversely, 
many people with hearing loss do not report tinnitus. 
People who report high levels of both occupational and 
recreational noise exposure are more likely to have 
tinnitus.9 Other factors such as obesity, smoking, alcohol 
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Search strategy and selection criteria
We searched Medline, Embase, and the Cochrane database for 
relevant studies, including systematic reviews, randomised 
controlled trials, basic scientiﬁ c reports, retrospective studies, 
prospective studies, cohort studies, and case reports published 
in any language between Jan 1, 1987, and Aug 31, 2012. We 
used the search terms “tinnitus” and “pulsatile tinnitus”. We 
also searched the reference lists of articles identiﬁ ed by this 
search strategy and selected those that we deemed relevant. 
We mainly focused on publications from the past 5 years, but 
have included commonly referenced and highly regarded 
older publications.
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consumption, previous head injuries, history of arthritis, 
and hypertension have been suggested as possible risk 
factors,3,9 and some results have suggested a small 
genetic predisposition.10 Various drugs can trigger 
tinnitus, including salicylates, quinine, aminoglycoside 
antibiotics, and some of the antineoplastic agents, 
particularly the platinum-based drugs.8 The condition 
can occur in association with several otological diseases, 
including otosclerosis, Ménière’s disease, and vestibular 
schwannoma (acoustic neuroma). Tinnitus also has 
several comorbidities, particularly anxiety, depres sion,11 
and dysfunction of the temporomandibular joint.12 
Decreased sound tolerance (hyperacusis) is a common 
accompanying symptom—deﬁ ned as an aversion to loud 
sounds, some degree of hyperacusis is noted in 40% of 
patients with tinnitus, and up to 86% of patients who 
report hyperacusis also report tinnitus.13
Several investigators have studied the localisation of 
tinnitus,14 and the consensus is that it is perceived in both 
ears or centrally within the head in roughly half of 
patients. Among the remainder, tinnitus is more 
frequently left-sided than right. A few people perceive it as 
an external sound or have diﬃ  culty deﬁ ning its location. 
The reason for left-sided preponderance is unknown and 
cannot be explained by asymmetric hearing loss.15
Incidence and longitudinal studies are scarce. In a 
study in Beaver Dam, WI, USA, for a cohort aged 
between 48 and 92 years, the prevalence of tinnitus at 
baseline was reported to be 8∙2%; notably, the 
participants tended to show improvement rather than 
worsening of their tinnitus during the study.16 The 5-year 
cumulative incidence of new cases of tinnitus was 5∙7% 
and the 10-year ﬁ gure was 12∙7%.16,17
Pathophysiological mechanisms
Because otological conditions, especially high-frequency 
hearing loss, present one of the major risk factors for 
tinnitus, the auditory phantom sensations are often 
deemed to be a neuroplastic response to sensory 
deprivation.18 Tinnitus is not simply a straightforward 
correlate of the imbalance of ﬁ ring patterns across the 
tonotopic array of the impaired cochlea, because the 
sound percept can persist even when input from the ear 
is eradicated by cutting of the auditory nerve.19 Although 
cochlear abnormalities could be the initial source of 
tinnitus, the subsequent cascade of neural changes in the 
central auditory system is more likely to maintain the 
condition. Much of what we know about tinnitus comes 
from studies of hearing loss in animals,18,20 but many 
questions are unanswered and some people have 
questioned the validity of these animal models.21 The 
current assumption is that the neural changes measured 
in the animal models of hearing loss are the neural 
correlates of the human clinical symptoms; however, this 
assumption has not yet been conﬁ rmed.22
An increased spontaneous ﬁ ring rate of neurons in the 
central auditory system is one possibility for the neural 
substrate of tinnitus. Cochlear hearing loss reduces 
cochlear nerve activity, and this reduced activity within 
the aﬀ ected peripheral auditory region downregulates 
inhibitory cortical processes. That downregulation leads 
to hyperexcitability within central auditory structures, 
including primary auditory cortex.23 Whether increases 
in spontaneous ﬁ ring rate are linked directly to the 
sensation of tinnitus is, however, unclear. Such changes 
take between hours and days to occur in the auditory 
structures, and this time course does not ﬁ t well to the 
perceived experience because tinnitus is often 
experienced immediately after noise exposure.23
Another possible mechanism is neural synchrony. 
Temporal synchrony in the ﬁ ring pattern across several 
neurons in primary auditory cortex increases immediately 
after a noise-induced hearing loss, particularly for 
neurons representing the aﬀ ected part of the tonotopic 
array.23,24 Increased neural synchrony also tends to be 
spatially coincident with changes in the frequency tuning 
properties of the same aﬀ ected neurons.24 In normal-
hearing animals, neurons selectively respond to charac-
teristic frequencies, and progression of frequency tuning 
in bands across distinct auditory ﬁ elds is orderly (tono-
topicity). Hearing loss results in disturbed tonotopicity 
in primary auditory cortex such that neurons with 
characteristic frequencies within the deprived region 
adopt the tuning properties of their less-aﬀ ected neigh-
bours, at the edge of the hearing loss.25 Nevertheless, one 
major psychoacoustic ﬁ nding is inconsistent with the 
claim that expansion of the tonotopic map at the 
audiometric edge underpins the tinnitus sensation—the 
dominant tinnitus pitch does not generally fall at the 
edge of the hearing loss.26,27 Instead, it falls somewhere 
within the region of hearing loss, consistent with neural 
temporal dynamics being the neural correlate of tinnitus.
Map reorganisation in the auditory modality after 
hearing loss has also been compared to map 
Speciﬁ c diseases or conditions
Otological, infectious Otitis media, labyrinthitis, mastoiditis
Otological, neoplastic Vestibular schwannoma, meningioma
Otological, labyrinthine Sensorineural hearing loss, Ménière’s disease, vestibular vertigo
Otological, other Impacted cerumen, otosclerosis, presbyacusis, noise exposure
Neurological Meningitis, migraine, multiple sclerosis, epilepsy
Traumatic Head or neck injury, loss of consciousness
Orofacial Temporomandibular joint disorder
Cardiovascular Hypertension
Rheumatological Rheumatoid arthritis
Immune-mediated Systemic lupus erythematosus, systemic sclerosis
Endocrine and metabolic Diabetes mellitus, hyperinsulinaemia, hypothyroidism, hormonal changes 
during pregnancy
Psychological Anxiety, depression, emotional trauma
Ototoxic medications Analgesics, antibiotics, antineoplastic drugs, corticosteroids, diuretics, 
immunosuppressive drugs, non-steroidal anti-inﬂ ammatory drugs, steroidal 
anti-inﬂ ammatory drugs8
Table: Known risk factors for developing tinnitus and conditions associated with tinnitus symptoms
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reorganisation in the somatosensory modality after 
amputation.28,29 A proposed model suggests that the 
tinnitus sensation might reach conscious awareness only 
when aberrant neuronal activity in the primary sensory 
cortex is connected to a broader cortical network 
involving frontal, parietal, and limbic brain regions.29 
Human neuroimaging evidence supports this notion by 
implicating not only the central auditory system, but also 
prefrontal and emotional centres in tinnitus.22,30
The heterogeneity of tinnitus in aetiology, patho physi-
ology, and clinical characteristics probably exacerbates the 
variable population response to tinnitus manage ment.31,32 
An eﬀ ective classiﬁ cation system informed by the patho-
physiological mechanisms underlying individual tinnitus 
symptoms would be a ground-breaking step towards 
personalised rehabilitation.32 Further basic research 
address ing the pathophysiology of tinnitus in animals and 
people therefore has an important clinical rationale.
Investigation and diagnosis
No objective test is available for most tinnitus cases, and 
diagnosis is made on the basis of medical history and an 
assessment of the eﬀ ect on the patient and his or her 
family. Important questions include the location and 
character of the tinnitus, particularly whether it has a 
rhythmical or pulsatile component. Pulsatile tinnitus can 
in rare cases be objectively detected by auscultation. 
Important questions about tinnitus consequences include 
its eﬀ ect on sleep and concentration. Several health 
questionnaires are available that assess the eﬀ ects of 
tinnitus, of which the tinnitus handicap inventory33 is the 
most commonly used in the UK,34 although the tinnitus 
functional index35 might replace it. Questionnaires to 
assess associated symptoms such as hyperacusis36 and 
psychological distress37 can also be helpful. Pure-tone 
audiometry (or age-appropriate equivalents for children) 
should be done, and, because many patients complain of a 
blocked sensation in the ears, tympanometry can be 
useful. Tests to match the pitch and loudness of the 
tinnitus are diﬃ  cult, relate poorly to the patient’s distress,38 
and oﬀ er little to the subsequent management plan. 
Patients who have asymmetric tinnitus, asymmetric 
hearing on pure-tone audiometry, or other associated 
neurological symptoms or signs need further investigation, 
and generally the chosen modality is MRI. Patients with 
heartbeat-synchronous pulsatile tinnitus need more 
detailed investigation by a complex algorithm that could 
include ultrasonography, CT, MRI, CT angiography, MR 
angiography, or conventional angiography.
Standard treatments
After treatable pathology associated with tinnitus has 
been excluded, standard care is to give an explanation of 
the situation (including both causation and the develop-
ment of associated distress), sound therapy (either 
hearing aids or sound generators), and, where needed, 
intervention to reduce the distress (relaxation therapy or 
cognitive behaviou ral therapy [CBT] or both). In England, 
the Department of Health has published a good practice 
guide for tinnitus care,39 which describes a stepped-care 
ap proach, with the primary-care physician oﬀ ering initial 
reassurance and diagnosis of simple remediable causes, 
such as cerumen or infection, and referral to secondary 
care when tinnitus is severe or associated with hearing 
loss. At this stage, in-depth counselling and sound 
therapy can be undertaken. A tertiary level of care is 
reserved for intractable or severe tinnitus and patients 
with otological pathology.
The heterogeneity of the disorder and the method-
ological challenges of undertaking controlled trials on 
counselling-based therapy have meant that evidence for 
the eﬃ  cacy of this approach is sparse. The few studies 
reported are generally poorly designed, and no standard 
outcome measure has been widely adopted.32 The 
individual elements have been investigated, but again the 
evidence base is poor. In a systematic review, the eﬃ  cacy of 
sound therapy approaches was inconclusive,40 though for 
many clinicians the practice of ﬁ tting hearing aids for 
individuals with tinnitus associated with hearing loss is 
axiomatic.41 The use of wideband sound therapy devices—
initially used to cover the tinnitus completely, and hence 
called maskers—is similarly unsupported by evidence.40 
Relax ation therapy does beneﬁ t patients.42 Formal CBT was 
shown to reduce tinnitus distress in systematic review and 
meta-analysis,43,44 although these studies involved patients 
suﬃ  ciently distressed as to warrant referral to a psychol-
ogist, and therapy was undertaken by expert practitioners, 
which could limit applicability to a general clinic.45
A prescriptive treatment protocol for tinnitus called 
tinnitus retraining therapy (TRT)46 includes counselling 
and sound-generator therapy. A systematic review showed 
the poor quality of research on TRT.47 We identiﬁ ed one 
trial in this review, and that work suggested that TRT is 
more eﬀ ective than masking.48 A subsequent trial used 
TRT as a control for acceptance and commitment 
therapy,49 which has developed from CBT. TRT had a 
small beneﬁ t in that study. The principle of TRT, which is 
to explain both ignition of tinnitus and development of 
distress, has been inﬂ uential on tinnitus work inter-
nationally, but its formal use is not widespread.
A randomised controlled trial compared the beneﬁ ts of 
the combination of counselling elements of CBT and 
TRT with standard care50—standard care being an ear, 
nose, and throat or audiology consultation and provision 
of a hearing aid or sound generator, or both, and input 
from a social worker. The specialised care was beneﬁ cial 
for quality of life and speciﬁ c metrics of tinnitus distress 
and annoyance, irrespective of the initial severity of the 
tinnitus. The eﬀ ect was thought to be due to reduction in 
the fear associated with tinnitus.
Emerging sound treatments
Several sound-based technological innovations have been 
commercially produced for tinnitus, with experimental 
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prototypes also being investigated.51 The manufacturers 
claim that these devices not only mask perception of 
tinnitus, but also are eﬀ ective through other ways. For 
some of these emerging sound treatments (eg, acoustic 
coordinated reset neuromodulation, sere nade, and 
frequency discrimination training), the sug gested target 
site of action is the central auditory system, with the 
sound individually tailored to the hearing loss and tinnitus 
characteristics to interrupt the maladaptive neuroplasticity 
driving the tinnitus sensation.51,52 Other interventions use 
sound mostly as a therapeutic relaxant (eg, Widex Zen53), 
while the Neuromonics device is said to reduce emotional 
arousal, and target the eﬀ ects of auditory deprivation 
through spectrally shaped sound.54
Typically, the commercial devices are recommended as 
part of a holistic audiological management programme 
that incorporates education and counselling. Such com-
bined approaches complicate the process of extrac tion of 
evidence for or against the eﬀ ectiveness and value of 
each sound treatment that is separate from any general 
psychological beneﬁ t of rehabilitation.40 Few trial data are 
available, so we conclude that emerging sound treatments 
on their own are of unproven beneﬁ t to tinnitus symptom 
reduction.51,55
Complementary and alternative medicine
Many individuals with tinnitus use complementary and 
alternative medicine, though no method has reduced 
tinnitus volume or associated distress. Many such 
treatments induce relaxation, which could beneﬁ t an 
agitated person with tinnitus, but this beneﬁ t would be 
indirect. The general caveats of the interaction of some 
complementary or alternative treatments with pre scribed 
medication apply, and a speciﬁ c concern is that the 
practice of ear candling could cause ear and facial burns.56
Brain stimulation
On the basis of knowledge showing tinnitus-related 
abnormalities in distinct regions of the central auditory 
system, possibly linked to high spontaneous neuronal 
activity,18,20,23 brain stimulation has been investigated as a 
way to decrease neuronal activity.
Repetitive transcranial magnetic stimulation uses non-
invasive electromagnetic induction to generate weak 
electrical currents in the brain, thus reducing neural 
excitability. A systematic review assessed ﬁ ve trials that 
compared this technique with a control, all with non-
navigated coil localisation.57 The ﬁ ndings showed limited 
support for use of low-frequency transcranial magnetic 
stimulation to reduce tinnitus volume or improve quality 
of life. Each trial described the use of a diﬀ erent device 
that delivered diﬀ erent waveforms at diﬀ erent stimulation 
rates; interpretation of the ﬁ ndings is diﬃ  cult, because 
the various stimulation protocols were diﬀ erentially 
beneﬁ cial for tinnitus. No serious adverse eﬀ ects were 
reported in any of the trials, but the long-term safety of 
this treatment is unknown.
In several studies patients with movement disorders and 
comorbid tinnitus who underwent deep brain stimulation 
for the movement disorder reported a reduction in tinnitus 
volume when the implant was switched on, without 
aﬀ ecting hearing.58,59 One study isolated the beneﬁ t to 
stimulation of area LC in the caudate nucleus.59 This brain 
region is not part of the classic auditory pathway, so these 
preliminary observations warrant further investigation.
Drug treatments
No drugs are licensed in Europe or North America for 
treatment of spontaneous idiopathic tinnitus, although 
many have been tried. A notable exception is local 
anaesthetics: in 1935, Bárány noted that intravenous 
injection of procaine temporarily alleviated tinnitus in 
most patients.60 Lidocaine61 and bupivacaine62 also have 
this eﬀ ect. Subsequent work has shown that the alleviation 
occurs within the central auditory pathways of the brain,63 
although an additional cochlear eﬀ ect cannot be excluded. 
However, intravenous injection of local anaesthetics 
carries too many risks for therapeutic use, and the 
alleviation has not been replicated with analogous but 
safer compounds,64,65 or by other administration routes.66
Drugs from several broad categories have been tested for 
eﬀ ect on tinnitus. Tricyclic antidepressants and selective 
serotonin-reuptake inhibitors are not eﬀ ective at reducing 
tinnitus,67 but they might have a role in management of 
any concomitant psychological distress. Favourable results 
have been reported from one study of the benzodiazepine 
alprazolam,68 but the research quality was not suﬃ  cient for 
reliable conclusions to be drawn. A more robust study of 
the same drug showed no change in the majority of 
outcome measures.69 Antispasmodic drugs70 and drugs for 
neuropathic pain71 are generally ineﬀ ective, although one 
trial showed a possible small eﬀ ect of gabapentin in a 
subgroup of patients with tinnitus secondary to acoustic 
trauma.72 Several anticonvulsant drugs have been tested, 
including amino-oxyacetic acid,73 lamotrigine,74 and 
carbamazepine,75 without success. Glutamate is the main 
excitatory neurotransmitter in the auditory system; 
consequently, various antagonist drugs have been investi-
gated. Studies of memantine,76 ﬂ utirpine,77 and nere-
mexane78 have not shown beneﬁ ts in tinnitus treatment. 
Investigation of glutamate antagonists continues.
Drugs aimed at improving microcirculation in both the 
central and peripheral auditory systems have been 
assessed. Diuretics,79 anticoagulants,80 and vasodilators81 
have been tried without success. The drug betahistine, 
licensed in Europe but not the USA, is thought to help 
Ménière’s disease by improving cochlear blood ﬂ ow. 
However, no available robust evidence suggests that 
betahistine is eﬀ ective in the tinnitus of Ménière’s 
disease,82 or supports its use in other types of tinnitus. 
Nevertheless, it continues to be widely prescribed.
Melatonin has been the subject of several trials, the 
results of which suggest it could help patients who have 
insomnia in association with tinnitus.83
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Some researchers have suggested that increasing intake 
of various dietary components, particularly vitamin B, 
zinc, and magnesium, could help tinnitus. Existing 
evidence is of poor quality and contradictory, although 
magnesium and several other vitamins and minerals are 
being investigated as potential otoprotectants.
Laser treatment
Low-level or soft laser therapy is used in some types of 
chronic pain management, although the mode of action 
remains conjectural. On the basis of similarities between 
chronic pain and tinnitus, lasers have been promoted by 
manufacturers for use in tinnitus (though no speciﬁ c 
mode of action is known), and several devices are 
commercially available. Although results of a few studies 
have suggested a beneﬁ t of laser therpay, most suggest 
that it is ineﬀ ective.84
Surgery for tinnitus
Surgery has a small but deﬁ nite role in tinnitus 
management. Its place with regard to pulsatile tinnitus 
and that associated with speciﬁ c conditions such as 
otosclerosis or Ménière’s disease is beyond the scope of 
this Seminar. Initial theories of tinnitus pathogenesis 
focused very much on the ear; consequently, the working 
hypothesis was that ablation of the cochlea or section of 
the cochlear nerve would eradicate tinnitus, albeit at the 
expense of causing total deafness in the aﬀ ected ear. Few 
studies of this treatment option have been done, and none 
that meet stringent scientiﬁ c standards. The available data 
show tinnitus improvement in 45%85 to 95% of patients,86 
but complete destruction of the hearing will always limit 
the applicability of this procedure.
The suggestion that some cases of tinnitus could be 
caused by blood vessels pressing against the auditory 
nerve arose from work on facial neuralgia. Surgery to 
decompress these neurovascular conﬂ icts could therefore 
oﬀ er a resolution of the symptoms in these cases; how-
ever, the evidence so far is conﬂ icting. Although some 
researchers have reported positive results,87 these are 
based on small numbers of patients. This type of surgery 
is best thought of as a preliminary experimental technique.
Cochlear implantation is one type of tinnitus research 
in which good evidence supports the eﬀ ect of the 
intervention.88 More than 80% of patients with bilateral 
profound sensorineural hearing loss have tinnitus. 
Cochlear implantation improves or eliminates tinnitus in 
up to 86% of these patients, although 9% report worse 
postoperative tinnitus. Of patients who do not have 
tinnitus initially, up to 4% develop it after surgery. 
Cochlear implantation is also being investigated as 
treatment for patients with single-sided profound 
sensorineural hearing loss and normal or near-normal 
hearing in the other ear. Although this approach will 
probably be appropriate for only a tiny proportion of 
patients with tinnitus, initial reports suggest that it is 
very successful in this subgroup.89
Variations in clinical practice
The clear gaps in evidence-based practice mean that 
linkage of assessment and diagnosis to the most eﬀ ective 
management strategies is diﬃ  cult.34,90 Therefore, although 
the epidemiology of tinnitus is broadly comparable across 
countries, international clinical practices diﬀ er (ﬁ gure). 
For acute subjective tinnitus, pharmacological pre-
scriptions are common, whereas for chronic subjective 
tinnitus, audiological and psychological approaches are 
more typical.91 Patterns of tinnitus management are 
highly country-speciﬁ c91—for example, pharmaceutical 
treatments are favoured over acoustic devices in Italy, but 
the reverse is true in the UK. Physical therapy is especially 
popular in France, Germany, and Italy.
Without a standard diagnostic algorithm or treatment 
pathway, the choice of treatment is largely up to 
individual clinical professionals, probably inﬂ uenced 
by country-speciﬁ c training routes and practices,91 
diﬀ erences in expenditure in hearing services,92 schemes 
for reimbursement from medical insurance,93 local 
resource limitations,94 and patients’ preference.
The capacity for self-referral by patients and the corres-
ponding point-of-entry into health care varies greatly 
between countries (ﬁ gure) but primary care physicians 
and otolaryngology specialists have substantial roles in 
referral and management in most. Other specialties are 
involved to a greater or lesser extent; examples are 
audiology (UK and USA) and neurology (Germany, Italy, 
and Spain) (ﬁ gure). In some countries—such as the UK, 
Scandinavia, the Netherlands, and the USA—audiology is 
 Figure: The range of pathways for tinnitus referrals to otolaryngology (ENT) specialists
Data taken from Hall.91 Sizes of the segments in the chart represent the relative proportions of referrals from each 
specialty based on information about the last ten tinnitus patients seen by individual ENT consultants.
USA UK Germany
Spain France Italy
Direct
General practitioner (GP) 
(or primary care physician)
ENT
Neurologist
Audiologist
Paediatrician
Psychotherapist
Surgeon
Other
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a recognised independent profession and practitioners 
provide assessment and rehabilitative health care for 
people with tinnitus and hearing prob lems.94–96 Elsewhere 
in Europe, audiology, and hence tinnitus provision, is 
encompassed in a sub-specialty of otolaryngology (eg, in 
Germany97). Otolaryngology trad itionally treats the physio-
logical aspect of tinnitus, but audiology practice typically 
addresses the functional eﬀ ect of the condition. Although 
many adults experience tinnitus-related distress suf-
ﬁ cient to severely aﬀ ect their quality of life,3 availability of 
appropriate specialist psychological support varies geo-
graphically both within and between countries.34,50
Clinical trials in tinnitus
Many diﬀ erent management strategies are used in clinical 
practice, but individuals have highly variable responses 
and evidence for beneﬁ t in most cases has not yet been 
conclusively shown.31,90 Although the need for eﬀ ective 
management options for tinnitus is clear, methodological 
and reporting quality of clinical trials have been low. 
Consequently, with the exception of CBT,43,44 evidence for 
the eﬀ ectiveness of diﬀ erent treat ment strategies is 
insuﬃ  cient.40,47,57,67,98 Investigators under taking a UK-wide 
consultation of patients and clinicians made a priority list 
of ten unanswered questions (panel),99,100 many of which 
could be addressed through high-quality randomised 
controlled trials.
Randomised trials are generally deemed to be the best 
experimental design for assessment of the eﬃ  cacy of a 
clinical intervention. Dobie31 reviewed 69 trials in tinnitus, 
but drew attention to weaknesses such as inadequate 
implementation of intervention, poor masking, incorrect 
methods of statistical analysis, absence of intention-to-
treat analysis, and low consensus on an appropriate 
outcome measure. A systematic review of 28 trials in 
tinnitus pinpointed similar ﬂ aws;98 although this search 
was limited to trials that used validated outcome measures, 
Hoare and colleagues98 reported little evidence of masking 
and poor external validity—only 25% of trials estimated 
sample size by use of a power calculation. The conclusions 
that can be made from these studies, and the scope for 
meta-analysis of trial data, are therefore limited.
Several research groups have made suggestions for 
methodological standards in tinnitus trials, to stimulate 
debate about how to improve methods and reporting,32,101 
drawing attention to guidelines for good clinical practice 
and reporting (eg, CONSORT102).
Prevention
Exposures to cytotoxic drugs, ototoxic antibiotics, and 
signiﬁ cant noise are recognised as factors that increase 
the risk of developing tinnitus. These factors are known 
to cause death of cochlear hair cells by apoptosis rather 
than necrosis.103 Apoptosis can potentially be blocked 
either before exposure to the injurious agent or for a 
short period afterwards. Research is therefore continuing 
to try to ﬁ nd agents that can block apoptosis. The action 
of antioxidants is attracting most attention, with 
D-methionine or a combination of betacarotene, 
vitamin C, vitamin E, and magnesium showing initial 
promise.104,105 Repair of cochlear damage by use of gene 
therapy and stem cell therapy is also being studied.103
Conclusion
Progress of research into tinnitus is clear, including 
systematic reviews of treatments, basic science research 
on mechanisms, and development of novel approaches to 
treatment. Once otological pathology has been excluded 
or treated, the treatment of choice for tinnitus involves the 
interweaving of education, sound therapy, and counselling, 
informed by the principles of CBT.50 Although the beneﬁ ts 
of such treatment are small, and the perception of tinnitus 
does not stop, it does improve quality of life and reduce 
awareness of, and reaction to, tinnitus.
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